BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

October 21, 2013 7:00 AM UTC

Alimera Science Inc. (NASDAQ:ALIM) fell $0.23 to $2.48 on Friday after FDA issued a complete response letter for an NDA for Iluvien fluocinolone acetonide intravitreal implant to treat diabetic macular edema. Alimera said FDA requested an additional clinical trial plus at least 12 months of follow-up. Alimera has rights to Iluvien from pSivida Corp. (NASDAQ:PSDV; ASX:PVA), which lost $0.93 (24%) to $2.87 on Friday. In Australia, the stock was down A$0.52 (12%) to A$3.84.

Alimera said it will meet with FDA's Dermatologic and Ophthalmic Drug Advisory Committee in January for advice. The complete response letter is the third from FDA for Iluvien...